Did you analyze how Exelixis (EXEL) fared in its international operations for the quarter ending December 2024? Given the widespread global presence of this drug developer, scrutinizing the trends in international revenues becomes imperative to assess its financial strength and future growth possibilities.In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health and growth trajectory. For inves ...

Exelixis, Inc. (EXEL) reported better-than-expected fourth-quarter results.EXEL recorded earnings of 55 cents per share, which beat the Zacks Consensus Estimate of 51 cents. The company registered adjusted earnings of 33 cents per share in the year-ago quarter. The outperformance was mainly driven by higher revenues.Including stock-based compensation expense, earnings were 48 cents per share in the reported quarter.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Net revenues were $566 ...

Exelixis (NASDAQ: EXEL ) has done well marketing the multi-kinase inhibitor, cabozantinib, bringing in $1.81B in net product revenues in 2024. The party will one day end, however, as EXEL has already agreed to allow generics manufacturerScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure: ...

Exelixis, Inc. (NASDAQ:EXEL) Q4 2024 Earnings Conference Call February 11, 2025 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs & Investor Relations Mike Morrissey - President & Chief Executive Officer Chris Senner - Chief Financial Officer PJ Haley - Executive Vice President, Commercial Amy Peterson - Chief Medical Officer Dana Aftab - Chief Scientific Officer Conference Call Participants Asthika Goonewardene - Truist Sean Laaman - Morgan Stanley David Lebowitz - Ci ...

For the quarter ended December 2024, Exelixis (EXEL) reported revenue of $566.76 million, up 18.2% over the same period last year. EPS came in at $0.55, compared to $0.33 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $563.12 million, representing a surprise of +0.65%. The company delivered an EPS surprise of +7.84%, with the consensus EPS estimate being $0.51.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Stree ...

TUESDAY, FEBRUARY 11, 2025 Fourth Quarter & Fiscal Year 2024 Financial Results Business Update and Highlights Financial Results & Guidance Q&A Susan Hubbard EVP, Public Affairs and Investor Relations Michael M. Morrissey, Ph.D. President and CEO Nasdaq: EXEL Today's Agenda Introduction Chris Senner EVP and CFO Amy Peterson, M.D. EVP, Product Development and Medical Affairs and CMO Dana T. Aftab, Ph.D. EVP, Discovery and Translational Research and CSO 2 Forward-Looking Statements This presentation, including ...

Exelixis (EXEL) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.33 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 7.84%. A quarter ago, it was expected that this drug developer would post earnings of $0.42 per share when it actually produced earnings of $0.47, delivering a surprise of 11.90%.Over the last four quarters, the company h ...

Exelixis reported increased revenue and earnings in Q4 2024, driven by strong cabozantinib sales, though competitive pressures and regulatory challenges remain.Exelixis (EXEL -2.06%), a biopharmaceutical company specializing in oncology treatments, released its fourth-quarter 2024 financial results, revealing a substantial rise in both revenue and earnings. Announced on Feb. 11, 2025, the earnings release showcased Exelixis's performance amidst a challenging oncology landscape, with revenues surpassing year ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 3, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-30235 EXELIXIS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or De ...

Exhibit 99.1 Investor Contacts: Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 shubbard@exelixis.com Media Contact: Hal Mackins For Exelixis, Inc. 415-994-0040 hal@torchcommunications.com Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner@exelixis.com Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025 – Cabozantinib franchise achieves approximately $1 ...